Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)‘s stock had its “market perform” rating reissued by stock analysts at FBR & Co in a research report issued to clients and investors on Wednesday. They presently have a $130.00 price target on the biopharmaceutical company’s stock. FBR & Co’s price objective points to a potential upside of 3.51% from the company’s current price.

Several other research analysts have also recently commented on the stock. Barclays PLC upgraded shares of Alexion Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $150.00 to $155.00 in a report on Tuesday. Piper Jaffray Cos. set a $176.00 price target on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, November 14th. Vetr upgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $142.00 price target for the company in a research note on Monday, November 14th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Alexion Pharmaceuticals in a research note on Friday, November 11th. Finally, Goldman Sachs Group Inc. reiterated a “buy” rating and issued a $158.00 price target on shares of Alexion Pharmaceuticals in a research note on Thursday, November 10th. One analyst has rated the stock with a sell rating, five have given a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $173.59.

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 125.59 on Wednesday. The company has a market cap of $28.15 billion, a P/E ratio of 76.58 and a beta of 1.45. The stock’s 50 day moving average is $122.56 and its 200 day moving average is $128.72. Alexion Pharmaceuticals has a 12-month low of $110.56 and a 12-month high of $193.45.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.23 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.04 by $0.19. Alexion Pharmaceuticals had a net margin of 12.46% and a return on equity of 10.58%. The business earned $799 million during the quarter, compared to analysts’ expectations of $787.07 million. During the same quarter in the prior year, the company posted $1.16 earnings per share. The firm’s revenue was up 19.9% on a year-over-year basis. On average, equities analysts forecast that Alexion Pharmaceuticals will post $4.64 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2016/11/30/alexion-pharmaceuticals-inc-alxn-given-market-perform-rating-at-fbr-co.html.

In related news, EVP Carsten Thiel sold 4,584 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Friday, October 14th. The shares were sold at an average price of $120.28, for a total transaction of $551,363.52. Following the sale, the executive vice president now directly owns 32,741 shares in the company, valued at approximately $3,938,087.48. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Leonard Bell sold 37,317 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $140.38, for a total transaction of $5,238,560.46. Following the sale, the director now owns 440,936 shares in the company, valued at $61,898,595.68. The disclosure for this sale can be found here. Corporate insiders own 4.41% of the company’s stock.

A number of large investors have recently bought and sold shares of ALXN. D.A. Davidson & CO. increased its stake in Alexion Pharmaceuticals by 27.5% in the third quarter. D.A. Davidson & CO. now owns 1,578 shares of the biopharmaceutical company’s stock valued at $191,000 after buying an additional 340 shares in the last quarter. Piedmont Investment Advisors LLC acquired a new stake in Alexion Pharmaceuticals during the third quarter valued at approximately $5,475,000. LPL Financial LLC increased its stake in Alexion Pharmaceuticals by 75.2% in the third quarter. LPL Financial LLC now owns 24,556 shares of the biopharmaceutical company’s stock valued at $3,030,000 after buying an additional 10,540 shares in the last quarter. Credit Suisse AG increased its stake in Alexion Pharmaceuticals by 3.1% in the third quarter. Credit Suisse AG now owns 596,567 shares of the biopharmaceutical company’s stock valued at $73,102,000 after buying an additional 17,715 shares in the last quarter. Finally, Ameritas Investment Partners Inc. increased its stake in Alexion Pharmaceuticals by 12.0% in the third quarter. Ameritas Investment Partners Inc. now owns 9,388 shares of the biopharmaceutical company’s stock valued at $1,150,000 after buying an additional 1,005 shares in the last quarter. Institutional investors and hedge funds own 94.85% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.